3Grandaliano G,Valente AJ,Rozek MM,et al.Gamma interferon stimulates monocyte chemotactic protein (MCP-1) in human mesangial cells[].Journal of Laboratory and Clinical Medicine.1994
4Ihm CG,Park JK,Hong SP,et al.A high glucose concentration stimulates the expression of monocyte chemotactic peptide-1 in human mesangial cells[].Nephron.1998
5Wenzel UO.Chemokines and renal disease[].American Journal of Kidney Diseases.1995
6Ruiz-ortega M,Bustos C,Hernandez-presa MA,et al.Angiotensin Ⅱ participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis[].J Immunol.1998
7Kim SY,Guijarro C,O′Donnell MP,et al.Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin[].Kidney International.1995
8Saitoh A,Sekizuka K,Hayashi T,et al.Detection of urinary MCP-1 in patients with diabetic nephropathy[].Nephron.1998
9Morrissey JJ,Klahr S.Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis[].American Journal of Physiology.
10Rovin BH,Doe N,Tan LC.Monocyte chemoattractant protein-1 levels in patients with glomerular disease[].American Journal of Kidney Diseases.1996
2Quatratro A,Giug LD,Ceriello A.New insights on nonenzymatic glycosylation maylead totherapeutic up proaches for the prevention of diabetic complication[J].Diabet Med,1992,9(3):297-302.
3The Diabetes Control and Complications Trail (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J]. New Engl J Med, 1993, 329(14) : 977-986.
4United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes[J]. Lancet,1998,352(9131) :837- 853.
